A plain-language account of the current scientific position, based on written responses provided to Hair of Istanbul by OrganTech, Inc. (Tokyo) on 8 September 2026. First published 16 September 2026.
Medically reviewed by Dr Mahmut Satekin, Medical Aesthetics Physician — 1 August 2026.
Hair of Istanbul
OrganTech, Inc., Tokyo, Japan
8 September 2026
1.0 — 16 September 2026
In August 2026 Hair of Istanbul wrote to OrganTech, Inc. and asked whether its research team would answer questions for our patient education material. OrganTech asked to see the questions in writing first. We submitted twelve questions on 31 August 2026, covering what the research has and has not shown, the biology, the manufacturing and safety requirements, which conditions might be addressed, how progress should be judged, and which terminology is accurate.
OrganTech returned written answers to all twelve questions on 8 September 2026. The scientific content of this document is drawn from those answers. Passages shown in quotation marks are OrganTech’s own words. Other scientific content is our plain-language summary of OrganTech’s responses, written for a non-specialist reader; where we have simplified, we have tried not to make a claim stronger than the one OrganTech made. Any commentary or patient-oriented guidance added independently by Hair of Istanbul is expressly identified as such and remains solely the editorial responsibility of Hair of Istanbul.
We have added no clinical claims of our own, and no claim about Hair of Istanbul’s services, to the scientific sections of this document.
OrganTech’s work rests on a method it developed in 2007, the organ germ method, in which two kinds of stem cell — epithelial and mesenchymal — are packed together at high density to reconstruct the seed of an organ.
In 2012, using that principle, OrganTech reported in animal studies that transplanting bioengineered hair follicle germs could regenerate hair that went through normal hair cycles.
The February 2026 study added the missing piece. Using three cell populations taken from adult mouse hair follicles — epithelial stem cells, dermal papilla cells, and the newly identified third population — OrganTech reported generating fully regenerated hair follicles in vitro that entered the growth (anagen) phase and produced hair shafts.
“These findings were obtained in animal studies. From a scientific perspective, however, the fundamental biological principles underlying hair follicle development and regeneration are considered to be broadly conserved in humans. We have also found a candidate cell population in human hair follicles that appears to correspond to the third cell population identified in our animal studies.”
OrganTech, Inc., written response, 8 September 2026
Follicle germs built from only two cell populations did form a hair bulb — but they stopped there. They did not progress into the growth phase, and they did not become complete, hair-producing follicles. OrganTech reasoned that something was missing, and reports that adding the third population enabled, for the first time, the generation of fully regenerated hair follicles in the laboratory.
| Finding | Shown in animals | Shown in humans |
|---|---|---|
| Bioengineered follicle germs regenerate hair that cycles normally | Yes (2012) | Not yet |
| Fully regenerated follicles produced in vitro from three cell populations | Yes (2026) | Not yet |
| Regenerated follicles integrate with arrector pili muscles and nerves | Yes | Not yet |
| Repeated hair cycles across the animal’s lifetime | Yes | Not yet |
| Position and density controllable by where germs are placed | Yes | Not yet |
| A corresponding third-cell population exists | Yes | Candidate identified; characterisation ongoing |
| Shaft diameter, pigmentation and curl pattern reproduced predictably | Not yet fully established; the dermal papilla is considered to play an important role in determining hair characteristics. | To be evaluated |
| Regulator-authorised human clinical study | — | Not yet begun |
OrganTech is explicit about the boundary:
“We are currently advancing the translational development required to apply these scientific principles to humans. However, these approaches have not yet reached clinical treatment or practical application in humans.”
OrganTech, Inc., written response, 8 September 2026
This is the distinction most often lost in public discussion, and OrganTech draws it sharply. The two approaches do different things, and they suit different patients.
What it does: introduces the third cell population into thinning areas to reactivate hair follicles the patient still has, encouraging them to move from the resting (telogen) phase into the growth (anagen) phase, and supporting the environment around the follicle.
Requires: existing follicles that remain in the scalp.
Does not: create new follicles. OrganTech states this “is not an organ-regeneration approach”.
Being investigated particularly for: female pattern hair loss, where resting-phase mechanisms are thought to play an important role.
What it does: isolates cells from the patient’s own follicles, expands them in the laboratory, and builds bioengineered hair follicle germs that are transplanted into areas of hair loss. A later variant would grow those germs into complete follicles first, then transplant them much as hair is transplanted today.
Requires: a small donor sample — not existing follicles in the treated area.
Does: increase the total number of follicles.
OrganTech’s analogy: the first transplants the “seed” of a follicle; the second grows it to the “seedling” stage before transplanting.
“One approach seeks to reactivate follicles that are already present, while the other seeks to regenerate and increase the number of follicles themselves.”
OrganTech, Inc., written response, 8 September 2026
A conventional hair transplant moves existing follicles from the back of the scalp to areas of loss. It redistributes; it cannot add. The total number of follicles a person has does not change.
Organ regeneration therapy is intended to change that number. OrganTech envisages an autologous approach — the patient’s own cells, taken from occipital follicles at the back of the scalp, which are the same follicles used in conventional transplantation because they resist androgenetic alopecia.
“We have already developed technology that allows hair follicle-regenerating stem cells to be expanded approximately 100-fold in vitro. In principle, therefore, if 10,000 hair follicles were required, approximately 100 donor follicles could provide the starting cellular material needed to generate them.”
OrganTech, Inc., written response, 8 September 2026
Two challenges stand in the way, and OrganTech names both: keeping the cells’ regenerative capacity stable while they are being multiplied, and building the technology to produce large numbers of uniform follicle germs.
Producing a hair shaft is not sufficient. A follicle has to behave like a follicle. In animal studies OrganTech reports that regenerated follicles cycled normally throughout the animal’s life and connected to the surrounding structures, including the arrector pili muscles and nerves — which suggests the natural direction and flow of hair could be reproduced.
The character of the hair itself — its calibre, colour and curl — is determined to a significant extent by the dermal papilla, so OrganTech expects follicles regenerated from occipital cells to retain the fundamental characteristics of the donor hair. Position and density, meanwhile, could be controlled by adjusting where and how many germs are placed.
All of this, OrganTech is careful to note, comes from animal work. Hair direction and angle, functional integration with surrounding tissue, shaft diameter, pigmentation and curl pattern — and how much each owes to the donor cells rather than the recipient scalp — remain to be evaluated in humans.
Before any human study, OrganTech states that a reproducible manufacturing process must exist — one that can culture and expand the cells while holding safety and quality steady. Specifically, it must be possible to confirm:
There is also a problem of scale that is easy to overlook. A bioengineered hair follicle germ is roughly 0.4 mm across, and several cell populations have to be compartmentalised inside it at high density.
“At present, this process is performed manually. An important technical challenge is therefore to automate the process so that large numbers of bioengineered hair follicle germs can be manufactured consistently, while also establishing efficient methods for culturing them in vitro.”
OrganTech, Inc., written response, 8 September 2026
OrganTech declined to disclose its specific manufacturing conditions and quality-control criteria, as these relate directly to its ongoing development programme.
Different forms of hair loss have fundamentally different causes, and OrganTech does not expect one regenerative treatment to fit them all.
| Condition | OrganTech’s position |
|---|---|
| Androgenetic alopecia male pattern hair loss | Mechanisms relatively well understood. Because occipital follicles resist it and would be the cell source, AGA is described as “one of the scientifically plausible indications” for organ regeneration therapy. Which patients would be appropriate for first clinical evaluation still has to be determined. |
| Female pattern hair loss | Causes remain incompletely understood. It is the focus of hope for the cell transplantation approach, because resting-phase mechanisms are thought to matter — but that approach requires follicles still to be present. |
| Alopecia areata Cicatricial (scarring) alopecias | Different disease mechanisms. OrganTech states plainly that it would be “premature to suggest that our therapeutic approaches will necessarily be applicable to these conditions.” |
Asked which publicly verifiable milestones would show genuine movement toward clinical use, OrganTech preferred milestones over projected dates: progress is better measured by asking whether specific scientific and technical problems have actually been solved.
| Milestone | Status |
|---|---|
| Development of the organ germ method | Achieved |
| Functional regeneration of hair follicle organs in animal models | Achieved |
| In vitro expansion of the stem cells required for regeneration | Achieved |
| Discovery of the third cell population | Achieved |
| Fully regenerated follicles in vitro using three cell populations | Achieved |
| Candidate corresponding cell population confirmed in human follicles | Achieved |
| Culture and expansion technology using human-derived cells | Remaining |
| Stable, standardised, scalable manufacturing | Remaining |
| Safety and quality-control systems | Remaining |
| Clinically feasible transplantation or cell administration methods | Remaining |
| Ethical and regulatory procedures completed | Remaining |
| Human clinical studies conducted | Remaining |
| Findings scientifically evaluated and published | Remaining |
Hair of Istanbul commentary — not part of OrganTech’s written responses
How to read a headline. If a news item or a clinic does not tell you which of the remaining milestones has been passed, it has not told you anything new. The first genuinely new thing to watch for is confirmation of regenerative function using human-derived cells.
OrganTech was direct about terminology, and this matters, because the loosest words travel furthest.
| Term | OrganTech’s assessment |
|---|---|
| “Hair follicle regeneration” or, broadly, “hair regeneration” | Considered the most appropriate general terms for the technology. |
| “Cell transplantation therapy using the third cell population” | Accurate name for the first approach. |
| “Hair follicle organ regeneration therapy” using bioengineered germs or regenerated follicles | Accurate name for the second approach. |
| “Hair cloning” | Intuitive to the public, but the technology “does not simply involve making copies of existing hairs.” |
| “Stem-cell hair transplant” | “Does not necessarily describe the actual therapeutic process accurately.” |
| Any wording implying availability | To be avoided: it must not be suggested that technologies still in research and development are established or clinically available treatments. |
Asked for the single most important message for someone experiencing hair loss, OrganTech opened with a sentence worth quoting in full — and then immediately qualified it.
“Hair regeneration is no longer simply a scientific aspiration.”
OrganTech, Inc., written response, 8 September 2026
After roughly two decades of work, OrganTech describes a foundation that now exists: the organ germ method, functional regeneration in animals, expansion of the necessary stem cells, the discovery of the third cell population, and fully regenerated follicles grown in the laboratory. Its stated objective is not to relocate a limited number of existing follicles, as conventional transplantation does, but ultimately to use a patient’s own cells to increase the number of follicles and regenerate them where they are needed.
“However, much of the evidence established to date has been obtained through animal studies, and these approaches have not yet been put into practical clinical use in humans… translating that potential into actual medical treatment requires rigorous confirmation of safety, quality, and reproducibility, together with careful and scientifically sound clinical development.”
OrganTech, Inc., written response, 8 September 2026
Both halves of that are the message. The science has moved, genuinely and substantially. It has not yet become a treatment, and nobody can offer it as one.
Hair of Istanbul commentary — not part of OrganTech’s written responses
Practically, for a patient today: decisions about hair loss still have to be made using the options that actually exist — medical treatment of ongoing loss, and hair transplantation, which redistributes the follicles you have. Because organ regeneration therapy would draw on cells from the occipital donor area, the donor area retains its importance in either future. A plan that exhausts it today does not become less costly because regenerative medicine may arrive later.
This document is also available as a PDF: Hair Follicle Regeneration: What Has Been Demonstrated, and What Has Not (10 pages). It sits alongside our other long-form documents in the Clinical Library.
Scientific content © OrganTech, Inc., reproduced with permission. Document © Hair of Istanbul. HOİ Sağlık Hizmetleri Turizm İnşaat Sanayi ve Ticaret A.Ş. · Ataköy, Bakırköy, Istanbul, Türkiye · Health institution licence: Certificate of Compliance No. 08/09/2010-37, Istanbul Provincial Health Directorate.
Get in touch for a free consultation. Our multilingual team is ready to answer your questions and guide you through the process.
Fill out the form and our team will contact you within 24 hours.
